Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Children with hepatitis C.

Maureen M Jonas1

  • 1Division of Gastroenterology, Children's Hospital Boston, MA 02115, USA. maureen.jonas@tch.harvard.edu

Hepatology (Baltimore, Md.)
|October 31, 2002
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) affects many children, with perinatal transmission being the primary cause. Research is needed to understand aggressive disease courses and optimize prevention and treatment strategies for pediatric HCV infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cross-Sectional Retrospective Review of Neuropsychiatric Comorbidities in Children With Non-Alcoholic Fatty Liver Disease.

Clinical pediatrics·2025
Same author

Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.

Journal of pediatric gastroenterology and nutrition·2024
Same author

ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings.

Journal of pediatric gastroenterology and nutrition·2024
Same author

Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.

Hepatology communications·2023
Same author

Presentation, Management, and Outcome of Congenital Portosystemic Shunts in Children: The Boston Children's Hospital Experience.

Journal of pediatric gastroenterology and nutrition·2022
Same author

Utilization of the Boston Children's Hospital SRTR Cohort Visualization Tool to increase team understanding of reporting cohorts.

Pediatric transplantation·2021
Same journal

Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease.

Hepatology (Baltimore, Md.)·2026
Same journal

AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation.

Hepatology (Baltimore, Md.)·2026
Same journal

H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis.

Hepatology (Baltimore, Md.)·2026
Same journal

Good vibrations: Using VCTE to predict hepatic decompensation in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

One size does not fit all: Global variability in noninvasive testing for MASLD.

Hepatology (Baltimore, Md.)·2026
See all related articles

Area of Science:

  • Pediatric Hepatology
  • Viral Hepatitis Epidemiology
  • Childhood Infectious Diseases

Background:

  • An estimated 240,000 children in the U.S. have hepatitis C virus (HCV) antibodies, with 68,000-100,000 chronically infected.
  • Acute HCV infection in children is often asymptomatic and undiagnosed, except in cases of known exposure.
  • While often benign, childhood HCV can progress to severe liver disease, with unknown contributing factors.

Purpose of the Study:

  • To highlight the significant burden of HCV in children.
  • To emphasize the need for research into risk factors for aggressive disease progression.
  • To underscore the importance of preventing perinatal HCV transmission and defining optimal treatment strategies.

Main Methods:

  • Review of existing epidemiological data on pediatric HCV infection.

Related Experiment Videos

  • Analysis of current understanding of HCV natural history in children.
  • Assessment of available therapeutic options and research gaps.

    • Main Results:

    • Perinatal transmission is the predominant route of new HCV infections in children.
    • Most chronically infected children are asymptomatic with normal liver enzymes.
    • Limited data exist on HCV therapy in children, with interferon monotherapy showing modest response rates (35-40%).

    Conclusions:

    • Prevention, especially of perinatal transmission, is crucial for managing pediatric HCV.
    • Further research is essential to identify factors influencing disease progression and to establish effective treatment protocols for children.
    • There is a critical need for large, randomized controlled trials to guide HCV management in pediatric populations.